Brain Tumor Biomarker Holds Steady at Recurrence, Reshaping Chemo Rechallenge Decisions
A large paired-cohort study finds MGMT promoter methylation remains quantitatively stable in 84 percent of recurrent gliomas, with apparent status ...
A large paired-cohort study finds MGMT promoter methylation remains quantitatively stable in 84 percent of recurrent gliomas, with apparent status ...
A first-in-kind pilot study reports that systemic targeted alpha therapy with actinium-225 labeled PSMA was feasible, well tolerated, and showed ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine